Actinogen Medical is a biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol.
The company is currently developing its lead compound, Xanamem®, as a revolutionary new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.
